Nicotinamide Mononucleotide Administration Prevents Doxorubicin-Induced Cardiotoxicity and Loss in Physical Activity in Mice.

Margier M, Kuehnemann C, Hulo N, Morales J, Ashok Kumaar PV, Cros C, Cannelle H, Charmetant J, Verdin E, Canault M, Grozio A

Cells27 Dec 2022Cited by 15 (Europe PMC)

PMID36611902PMCIDPMC9818647DOI10.3390/cells12010108PepBankPUB-36611902

Download PDF PubMedAsk about this study

Jump to 12 results

Summary

Doxorubicin (Doxo) is a widely used antineoplastic drug with limited clinical application due to its deleterious dose-related side effects. We investigated whether nicotinamide mononucleotide (NMN) could protect against Doxo-induced cardiotoxicity and physical dysfunction in vivo. To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic. In the acute study, C57BL6/J (B6) mice were injected intraperitoneally (i.p.) once with Doxo (20 mg/kg) and NMN (180 mg/kg/day, i.p.) was administered daily for five days before and after the Doxo injection. In the chronic study, B6 mice received a cumulative dose of 20 mg/kg Doxo administered in fractionated doses for five days. NMN (500 mg/kg/day) was supplied in the mice's drinking water beginning five days before the first injection of Doxo and continuing for 60 days after. We found that NMN significantly increased tissue levels of NAD+ and its metabolites and improved survival and bodyweight loss in both experimental models. In addition, NMN protected against Doxo-induced cardiotoxicity and loss of physical function in acute and chronic studies, respectively. In the heart, NMN prevented Doxo-induced transcriptomic changes related to mitochondrial function, apoptosis, oxidative stress, inflammation and p53, and promyelocytic leukemia nuclear body pathways. Overall, our results suggest that NMN could prevent Doxo-induced toxicity in heart and skeletal muscle.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In acute and chronic doxorubicin mouse models, NMN significantly increased tissue NAD+ levels.
In plain wordsIn mice exposed to doxorubicin, NMN increased tissue NAD+ levels in both models.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseTissue NAD+ levels
Study
mousen: not reported in source
C57BL6/J mice with doxorubicin toxicity
Outcome group
Receptor activity and mechanism · Whole body
Studied dose
Dose not stated
Source sentences
Summary
We found that NMN significantly increased tissue levels of NAD+ and its metabolites and improved survival and bodyweight loss in both experimental models.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic.
Show in the study text Report a problemFND-3661190201
02AnimalAnimal study (in vivo)Mechanism
In acute and chronic doxorubicin mouse models, NMN significantly increased tissue NAD+ metabolites.
In plain wordsIn mice exposed to doxorubicin, NMN increased tissue NAD+ metabolites in both models.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseTissue NAD+ metabolites
Study
mousen: not reported in source
C57BL6/J mice with doxorubicin toxicity
Outcome group
Receptor activity and mechanism · Whole body
Studied dose
Dose not stated
Source sentences
Summary
We found that NMN significantly increased tissue levels of NAD+ and its metabolites and improved survival and bodyweight loss in both experimental models.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic.
Show in the study text Report a problemFND-3661190202
03AnimalAnimal study (in vivo)Efficacy outcome
In acute and chronic doxorubicin mouse models, NMN improved survival.
In plain wordsIn mice exposed to doxorubicin, NMN improved survival in both models.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseSurvival
Study
mousen: not reported in source
C57BL6/J mice with doxorubicin toxicity
Outcome group
Mortality · Whole body
Studied dose
Dose not stated
Source sentences
Summary
We found that NMN significantly increased tissue levels of NAD+ and its metabolites and improved survival and bodyweight loss in both experimental models.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic.
Show in the study text Report a problemFND-3661190203
04AnimalAnimal study (in vivo)Efficacy outcome
In acute and chronic doxorubicin mouse models, NMN improved bodyweight loss.
In plain wordsIn mice exposed to doxorubicin, NMN reduced bodyweight loss in both models.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseBodyweight loss
Study
mousen: not reported in source
C57BL6/J mice with doxorubicin toxicity
Outcome group
Body weight · Whole body
Studied dose
Dose not stated
Source sentences
Summary
We found that NMN significantly increased tissue levels of NAD+ and its metabolites and improved survival and bodyweight loss in both experimental models.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic.
Show in the study text Report a problemFND-3661190204
05AnimalAnimal study (in vivo)Efficacy outcome
In the acute doxorubicin mouse study, NMN protected against cardiotoxicity.
In plain wordsIn mice in the acute doxorubicin study, NMN protected against heart toxicity.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseCardiotoxicity
Study
mousen: not reported in source
C57BL6/J mice with doxorubicin toxicity
Outcome group
Heart function · Cardiovascular
Studied dose
180 mg/kg/day · intraperitoneal · Daily for five days before and after the Doxo injectionAs given in this study (mouse).
Source sentences
Summary
In addition, NMN protected against Doxo-induced cardiotoxicity and loss of physical function in acute and chronic studies, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
In the acute study, C57BL6/J (B6) mice were injected intraperitoneally (i.p.) once with Doxo (20 mg/kg) and NMN (180 mg/kg/day, i.p.) was administered daily for five days before and after the Doxo injection.
Summary · context
To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic.
Show in the study text Report a problemFND-3661190205
06AnimalAnimal study (in vivo)Efficacy outcome
In the chronic doxorubicin mouse study, NMN protected against physical function loss.
In plain wordsIn mice in the chronic doxorubicin study, NMN protected against loss of physical function.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreasePhysical function loss
Study
mousen: not reported in source
C57BL6/J mice with doxorubicin toxicity
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
500 mg/kg/day · drinking water · Beginning five days before the first Doxo injection and continuing for 60 days afterAs given in this study (mouse).
Source sentences
Summary
In addition, NMN protected against Doxo-induced cardiotoxicity and loss of physical function in acute and chronic studies, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
NMN (500 mg/kg/day) was supplied in the mice's drinking water beginning five days before the first injection of Doxo and continuing for 60 days after.
Summary · context
To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic.
Show in the study text Report a problemFND-3661190206
07Computer modelIn silicoMechanism
In doxorubicin-exposed mice, NMN prevented heart transcriptomic changes related to mitochondrial function.
In plain wordsIn mice exposed to doxorubicin, NMN prevented heart gene-expression changes related to mitochondrial function.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseMitochondrial function transcriptomic changes
Study
mousen: not reported in source
Heart transcriptomic pathway analysis
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
In the heart, NMN prevented Doxo-induced transcriptomic changes related to mitochondrial function, apoptosis, oxidative stress, inflammation and p53, and promyelocytic leukemia nuclear body pathways.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic.
Show in the study text Report a problemFND-3661190207
08Computer modelIn silicoMechanism
In doxorubicin-exposed mice, NMN prevented heart transcriptomic changes related to apoptosis.
In plain wordsIn mice exposed to doxorubicin, NMN prevented heart gene-expression changes related to apoptosis.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseApoptosis transcriptomic changes
Study
mousen: not reported in source
Heart transcriptomic pathway analysis
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
In the heart, NMN prevented Doxo-induced transcriptomic changes related to mitochondrial function, apoptosis, oxidative stress, inflammation and p53, and promyelocytic leukemia nuclear body pathways.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic.
Show in the study text Report a problemFND-3661190208
09Computer modelIn silicoMechanism
In doxorubicin-exposed mice, NMN prevented heart transcriptomic changes related to oxidative stress.
In plain wordsIn mice exposed to doxorubicin, NMN prevented heart gene-expression changes related to oxidative stress.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseOxidative stress transcriptomic changes
Study
mousen: not reported in source
Heart transcriptomic pathway analysis
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
In the heart, NMN prevented Doxo-induced transcriptomic changes related to mitochondrial function, apoptosis, oxidative stress, inflammation and p53, and promyelocytic leukemia nuclear body pathways.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic.
Show in the study text Report a problemFND-3661190209
10Computer modelIn silicoMechanism
In doxorubicin-exposed mice, NMN prevented heart transcriptomic changes related to inflammation.
In plain wordsIn mice exposed to doxorubicin, NMN prevented heart gene-expression changes related to inflammation.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseInflammation transcriptomic changes
Study
mousen: not reported in source
Heart transcriptomic pathway analysis
Outcome group
Inflammation markers · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
In the heart, NMN prevented Doxo-induced transcriptomic changes related to mitochondrial function, apoptosis, oxidative stress, inflammation and p53, and promyelocytic leukemia nuclear body pathways.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic.
Show in the study text Report a problemFND-3661190210
11Computer modelIn silicoMechanism
In doxorubicin-exposed mice, NMN prevented heart transcriptomic changes related to p53 pathways.
In plain wordsIn mice exposed to doxorubicin, NMN prevented heart gene-expression changes related to p53 pathways.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Decreasep53 pathway transcriptomic changes
Study
mousen: not reported in source
Heart transcriptomic pathway analysis
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
In the heart, NMN prevented Doxo-induced transcriptomic changes related to mitochondrial function, apoptosis, oxidative stress, inflammation and p53, and promyelocytic leukemia nuclear body pathways.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic.
Show in the study text Report a problemFND-3661190211
12Computer modelIn silicoMechanism
In doxorubicin-exposed mice, NMN prevented heart transcriptomic changes related to promyelocytic leukemia nuclear body pathways.
In plain wordsIn mice exposed to doxorubicin, NMN prevented heart gene-expression changes related to promyelocytic leukemia nuclear body pathways.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreasePromyelocytic leukemia nuclear body pathway changes
Study
mousen: not reported in source
Heart transcriptomic pathway analysis
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
In the heart, NMN prevented Doxo-induced transcriptomic changes related to mitochondrial function, apoptosis, oxidative stress, inflammation and p53, and promyelocytic leukemia nuclear body pathways.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the short- and long-term toxicity, two Doxo regimens were tested, acute and chronic.
Show in the study text Report a problemFND-3661190212

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.